NCT06538389 2026-04-15
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
Phase 2 Suspended
Clinical Trials
16 trialsNCT07443943 2026-04-14
AIMSS-RPS
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT02928978 2026-04-13
TBCRC042
Baylor Breast Care Center
Phase 2 Completed
NCT05941520 2026-04-13
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06184750 2026-04-13
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06195306 2026-04-13
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04570956 2026-01-23
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
Mayo Clinic
Phase 2 Terminated
NCT03345420 2025-12-30
NOVEMBER
University of Utah
Phase 2 Completed
NCT01245712 2025-12-17
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06008158 2025-12-10
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca
City of Hope Medical Center
Phase 2 Suspended
NCT06153836 2025-12-04
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
Mayo Clinic
Phase 2 Recruiting
NCT06843681 2025-11-28
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Enrolling by invitation
NCT03979508 2025-11-12
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT06033092 2025-08-28
TOLERANT
European Institute of Oncology
Phase 2 Active not recruiting
NCT07044310 2025-07-29
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss
Mayo Clinic
Phase 2 Recruiting
NCT04290897 2025-07-15
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
Jonsson Comprehensive Cancer Center
Phase 2 Completed